Search results for "General Pharmacology"

showing 10 items of 356 documents

Local adaptation in populations of Mycobacterium tuberculosis endemic to the Indian Ocean Rim

2021

24 páginas, 3 figuras, 1 tabla. The sequence data generated by this study has been deposited on SRA (https://www.ncbi.nlm.nih.gov/sra) under the accession number PRJNA670836. Extended data is available here: https://github.com/fmenardo/MTBC_L1_L3. DOI: https://doi.org/10.5281/zenodo.4609804 (Menardo, 2021).

0301 basic medicineMycobacterium tuberculosis / patogenicidadeTuberculosisGenotypevirusesLineage (evolution)030106 microbiologyLocus (genetics)adaptationBiologyGenomeGeneral Biochemistry Genetics and Molecular BiologyMycobacterium tuberculosis03 medical and health sciencesAdapta??oGenoma BacterianomedicineHumansOceano ?ndico / epidemiologiaGeneral Pharmacology Toxicology and PharmaceuticsAdaptationIndian OceanLocal adaptationGenetic diversityGeneral Immunology and Microbiologyvirus diseasesTuberculose / patologiaGeneral MedicineArticlesMycobacterium tuberculosisbiochemical phenomena metabolism and nutritionbiology.organism_classificationmedicine.diseasedigestive system diseases3. Good health030104 developmental biologyMycobacterium tuberculosis complexEvolutionary biologycoevolutionLinhagemCoevolutionResearch ArticleF1000Research
researchProduct

Complex Regulatory Networks Governing Production of the Glycopeptide A40926

2018

Glycopeptides (GPAs) are an important class of antibiotics, with vancomycin and teicoplanin being used in the last 40 years as drugs of last resort to treat infections caused by Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus. A few new GPAs have since reached the market. One of them is dalbavancin, a derivative of A40926 produced by the actinomycete Nonomuraea sp. ATCC 39727, recently classified as N. gerenzanensis. This review summarizes what we currently know on the multilevel regulatory processes governing production of the glycopeptide A40926 and the different approaches used to increase antibiotic yields. Some nutrients, e.g., valine, l-glutamine and mal…

0301 basic medicineMicrobiology (medical)medicine.drug_class030106 microbiologyAntibioticsInfectious DiseaseReviewGlycopeptide antibioticBiologyLuxR solomedicine.disease_causeBiochemistryMicrobiologyMicrobiology03 medical and health sciencesStrRValinemedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsA40926Regulatory geneRegulator geneTeicoplaninlcsh:RM1-950DalbavancinLALA40926; Dalbavancin; Dbv cluster; Glycopeptide antibiotics; LAL; LuxR solo; Regulatory genes; StrR; Microbiology; Biochemistry; Pharmacology Toxicology and Pharmaceutics (all); Microbiology (medical); Infectious Diseases; Pharmacology (medical)regulatory genesGlycopeptidelcsh:Therapeutics. PharmacologyInfectious DiseasesDalbavancinStaphylococcus aureusPharmacology Toxicology and Pharmaceutics (all)Dbv clusterVancomycinglycopeptide antibioticsmedicine.drugAntibiotics
researchProduct

An Analysis of the Immunomodulatory Properties of Human Spheroids from Adipose-Derived Stem Cells

2023

Aims Current methods to induce tolerance following allotransplantation or in autoimmunity carry significant morbidity, and research is very active in investigating alternative methods which could minimize toxicity. Spheroids from adipose stem cells (SASCs) are increasingly gaining interest, they hold a great proliferative and differentiating potential. An immunomodulatory effect has not been investigated on SASCs yet. In this study, we analysed the immunomodulatory properties of SASCs and compared them to ADSCs. Main methods Adipose stem cells (SASCs and ADSCs) and peripheral blood mononuclear cells (PBMCs) were collected from healthy individuals. We analysed the cytokine production and pro…

HistoryPolymers and PlasticsGeneral MedicineGeneral Pharmacology Toxicology and PharmaceuticsBusiness and International ManagementImmunosuppression Adipose tissue Spheroids of adipose stem cell Cell therapyGeneral Biochemistry Genetics and Molecular BiologyIndustrial and Manufacturing EngineeringSSRN Electronic Journal
researchProduct

MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate

2019

Polo-like kinase (PLK1) has been identified as a potential target for cancer treatment. Although a number of small molecules have been investigated as PLK1 inhibitors, many of which showed limited selectivity. PLK1 harbors a regulatory domain, the Polo box domain (PBD), which has a key regulatory function for kinase activity and substrate recognition. We report on 3-bromomethyl-benzofuran-2-carboxylic acid ethyl ester (designated: MCC1019) as selective PLK1 inhibitor targeting PLK1 PBD. Cytotoxicity and fluorescence polarization-based screening were applied to a library of 1162 drug-like compounds to identify potential inhibitors of PLK1 PBD. The activity of compound MC1019 against the PLK1…

PBD Polo box domainMTD maximal tolerance doseCDC25 cell division cycle 25HIF-1α hypoxia-inducible factor 1 αMST microscale thermophoresisIC50 50% inhibition concentrationMFP M phase promoting factorPARP-1 poly(ADP-ribose) polymerase-10302 clinical medicineFOXO forkhead box ONec-1 necrostatin 1CDC2 cell division cycle protein 2 homologGeneral Pharmacology Toxicology and PharmaceuticsMitotic catastropheCDK cyclin-dependent kinase0303 health sciencesChemistryPolo-like kinaseMono-targeted therapyCell cycleBUBR1 budding uninhibited by benzimidazole-related 1Polo box domain030220 oncology & carcinogenesisPLK1 Polo-like kinaseNecroptosisSpindle damagePLK1IHC immunohistochemistryOriginal articleNecroptosisCell cyclePLK1APC/C anaphase-promoting complex/cyclosomePLK3ABC avidin-biotin complexPI propidium iodide03 medical and health sciencesFBS fetal bovine serumPDB Protein Data BankKd the dissociation constantKinase activity030304 developmental biologyAkt/PKB signaling pathwayCell growthlcsh:RM1-950LC3 light chain 3lcsh:Therapeutics. PharmacologyCancer researchDAPKs death-associated protein kinase3-MA 3-methyladenineDAPI 4′6-diamidino-2-phenylindoleSAC spindle assembly checkpointActa Pharmaceutica Sinica B
researchProduct

Toxicology and Risk Assessment: A Comprehensive Introduction, 2nd Edition. Edited by Helmut Greim and Robert Snyder

2019

PharmacologyOrganic ChemistryDrug DiscoveryMolecular MedicineLibrary scienceSociologyGeneral Pharmacology Toxicology and PharmaceuticsRisk assessmentBiochemistryChemMedChem
researchProduct

In vivo release of non-neuronal acetylcholine from human skin by dermal microdialysis: Effects of sunlight, UV-A and tactile stimulus

2007

Non-neuronal acetylcholine (ACh) is expressed in epithelial, endothelial and immune cells. For example, the in vivo release of ACh from the human skin pretreated with botulinum toxin has recently been demonstrated. In the present experiments the effects of light (sunlight and solar radiation by a commercial UV-A applier) and of a tactile stimulus on the release of non-neuronal ACh were investigated. Release of ACh from the proximal and distal shin, i.e. anterior tibial region, was measured by dermal microdialysis in 20 min samples over a time period of at least 140 min. Control experiments were performed in a dark room throughout. In some experiments volunteers were exposed to sunshine (80-…

AdultMaleMicrodialysisTime FactorsInjections IntradermalUltraviolet RaysMicrodialysisHuman skinStimulus (physiology)General Biochemistry Genetics and Molecular BiologyIn vivoPhysical StimulationmedicineHumansGeneral Pharmacology Toxicology and PharmaceuticsSkinNeuronsSunlightChemistryGeneral MedicineAnatomyAcetylcholineNon neuronal acetylcholineDermal microdialysisSunlightBiophysicsFemaleAcetylcholinemedicine.drugLife Sciences
researchProduct

Comparison of Fluoroquinolones and Other Antibiotic Prophylaxis Regimens for Preventing Complications in Patients Undergoing Transrectal Prostate Bio…

2022

Our study aimed to compare the incidence of infective complications after transrectal ultrasound-guided prostate biopsy (TRUSBx) when adopting different antimicrobial prophylaxis regimens. A multi-institutional cohort of 1150 patients who underwent TRUSBx was retrospectively analyzed. Procedures were performed between 2017 and 2019 (before and after the EMA warning about the use of fluoroquinolones for the antibiotic prophylaxis of patient candidates to TRUSBx). The primary endpoint was the occurrence of infective complications, including sepsis and/or fever. The population was stratified according to the antibiotic prophylaxis adopted: fluoroquinolones (levofloxacin, ciprofloxacin, prulifl…

Microbiology (medical)Infectious Diseasesantibiotic prophylaxisantibiotic prophylaxis; fluoroquinolones; prostate biopsyantibiotic prophylaxiprostate biopsy; antibiotic prophylaxis; fluoroquinolonesPharmacology (medical)prostate biopsyfluoroquinolonesGeneral Pharmacology Toxicology and PharmaceuticsfluoroquinoloneBiochemistryMicrobiology
researchProduct

Effect of laser treatment on postural control parameters in patients with chronic nonspecific low back pain: a randomized placebo-controlled trial

2019

The management of nonspecific lumbar pain (NSLP) using laser irradiation remains controversial. A systematic review of recently published studies indicates that the effects of laser therapy are commonly assessed using only imperfect methods in terms of measurement error. The main objective of this study was to assess static postural stability using an objective tool in patients with chronic NSLP after laser irradiation at different doses and wavelengths. In total, 68 patients were included in the laser sessions and were randomly assigned into four groups: high-intensity laser therapy at 1064 nm and 60 J/cm2 for 10 min (HILT), sham (HILT placebo), low-level laser therapy at 785 nm and 8 J/cm…

0301 basic medicineAdultMaleMedicine (General)QH301-705.5PhysiologyImmunologyBiophysicsPlacebo-controlled studyOcean EngineeringPlaceboBiochemistrylaw.invention03 medical and health sciencesR5-9200302 clinical medicineLumbarRandomized controlled trialLaser therapylawPostural BalanceMedicineHumansLow back painBiology (General)General Pharmacology Toxicology and PharmaceuticsLead (electronics)Pain Measurementbusiness.industryPhysical therapy modalitiesGeneral NeuroscienceCell BiologyGeneral MedicineMiddle AgedLow back pain030104 developmental biologyTreatment Outcome030220 oncology & carcinogenesisAnesthesiaPostural balanceChronic DiseaseFemaleAnalysis of variancemedicine.symptombusinessResearch ArticleFollow-Up StudiesBrazilian Journal of Medical and Biological Research
researchProduct

Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia.

2017

Several novel single nucleotide polymorphisms (SNPs) involved in cytarabine cytotoxicity and related to clinical outcomes have been reported recently in a series of 232 pediatric patients with acute myeloid leukemia (AML). We report the first adult AML cohort in which the influence of these SNPs in cytarabine efficacy and toxicity was analyzed. Six of polymorphisms with clinical significance in the previous study [rs12036333, rs10758713, rs9883101, rs6550826, IRX2: rs2897047, mutated in colorectal cancers (MCC): rs7729269] were analyzed in a cohort of 225 adult patients at initial diagnosis of AML treated with an induction scheme of idarubicin plus cytarabine. The variant alleles of rs12036…

0301 basic medicineOncologyAdultmedicine.medical_specialtyAdolescentPopulationSingle-nucleotide polymorphismKaplan-Meier EstimatePolymorphism Single NucleotideDisease-Free Survival03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineGeneticsmedicineIdarubicinHumansGeneral Pharmacology Toxicology and PharmaceuticseducationProspective cohort studyMolecular BiologyGenetics (clinical)Agededucation.field_of_studybusiness.industryCytarabineInduction chemotherapyMyeloid leukemiaInduction ChemotherapyMiddle AgedMinor allele frequencyLeukemia Myeloid Acute030104 developmental biology030220 oncology & carcinogenesisCytarabineMolecular Medicinebusinessmedicine.drugPharmacogenetics and genomics
researchProduct

Occurrence and Antimicrobial Resistance of Arcobacter spp. Recovered from Aquatic Environments

2021

Arcobacter spp. are emerging waterborne and foodborne zoonotic pathogens responsible for gastroenteritis in humans. In this work, we evaluated the occurrence and the antimicrobial resistance profile of Arcobacter isolates recovered from different aquatic sources. Besides, we searched for Arcobacter spp. in seaweeds and the corresponding seawater samples. Bacteriological and molecular methods applied to 100 samples led to the isolation of 28 Arcobacter isolates from 27 samples. The highest prevalence was detected in rivers followed by artificial ponds, streams, well waters, and spring waters. Seaweeds contained a higher percentage of Arcobacter than the corresponding seawater samples. The is…

0301 basic medicineMicrobiology (medical)Water samplesVeterinary medicineAntibiotic susceptibilityArcobacter cryaerophilusTetWTetracyclinemedicine.drug_class030106 microbiologyAntibioticsTetOBiochemistryMicrobiologyArticle03 medical and health sciencesAntibiotic resistancemedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsbiologyAquatic ecosystemlcsh:RM1-950Arcobacter butzleri<i>Arcobacter butzleri</i>Multiplex PCRbiology.organism_classificationIsolation (microbiology)Arcobacter butzlerilcsh:Therapeutics. Pharmacology030104 developmental biologyInfectious DiseasesArcobacter<i>tetO</i><i>tetW</i>medicine.drugAntibiotics
researchProduct